HomeQuestion
Would you use olaparib after progression on an ARPI for a patient with somatic PALB2 mutated mCRPC?
2
1 Answers
Mednet Member
Medical Oncology · University of Minnesota–Masonic Cancer Center
Yes, I would consider using olaparib monotherapy in a sPALB2-altered patient who has previously received one or more ARPI agents. This is based on a recent meta-analysis conducted by the FDA. In that paper, in PALB2-mutated mCRPC patients (N total = 41) rPFS HR was 0.52 (0.23 to 1.17) and OS HR was ...